CFO at Adicet Bio (ACET) receives stock options on 43,361 shares

Rhea-AI Filing Summary

Adicet Bio, Inc. reported that Chief Financial Officer Brian Nicholas received a grant of stock options covering 43,361 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. According to the vesting terms, 1/48th of the options vest on each monthly anniversary of the grant over forty-eight months, as long as he continues his service relationship with the company. Following this grant, he holds 43,361 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Harvey Brian Nicholas

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	43,361	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 43,361 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harvey Brian Nicholas

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.81	03/25/2026		A		43,361		(1)	03/24/2036	Common Stock	43,361	$0.00	43,361	D

Explanation of Responses:

1. (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

	/s/ Nick Harvey	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Adicet Bio (ACET) report for its CFO?

Adicet Bio reported that its Chief Financial Officer, Brian Nicholas, received a grant of stock options for 43,361 shares of common stock. These options were awarded as a compensation-related grant rather than an open-market purchase or sale of shares.

What are the key terms of the Adicet Bio CFO’s new stock options?

The CFO’s stock options cover 43,361 shares of Adicet Bio common stock at an exercise price of $6.81 per share. The options expire on March 24, 2036, providing a long-dated incentive aligned with the company’s future performance and his continued employment.

How do the Adicet Bio CFO stock options vest over time?

The options vest in equal monthly installments. Specifically, 1/48th of the 43,361 options vests on each of the forty-eight monthly anniversaries of the grant date, provided Brian Nicholas maintains a service relationship with Adicet Bio on each applicable vesting date.

Was the Adicet Bio CFO transaction a stock purchase or sale?

The transaction was neither an open-market purchase nor a sale. It was coded as an “A” transaction, meaning a grant or award of derivative securities. The CFO received stock options as compensation, with no cash transaction in the market reported in this filing.

How many Adicet Bio options does the CFO hold after this grant?

After this grant, the filing shows the CFO directly holding 43,361 stock options. This total matches the number of options awarded in the reported transaction, indicating this grant accounts for the full derivative position disclosed in the document.